Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Articles

RNA interference of IL-10 in leukemic B-1 cells

Brian A. McCarthy, Amal Mansour, Yi-Chu Lin, Sergei Kotenko and Elizabeth Raveche
Brian A. McCarthy
UMDNJ-New Jersey Medical School, Department of Pathology and Laboratory Medicine, Newark, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amal Mansour
UMDNJ-New Jersey Medical School, Department of Pathology and Laboratory Medicine, Newark, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Chu Lin
UMDNJ-New Jersey Medical School, Department of Pathology and Laboratory Medicine, Newark, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergei Kotenko
UMDNJ-New Jersey Medical School, Department of Pathology and Laboratory Medicine, Newark, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Raveche
UMDNJ-New Jersey Medical School, Department of Pathology and Laboratory Medicine, Newark, NJ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2004
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    RNAi modeling and annealing. (A) An idealized model of RNA folding for IL-10 based on enthalpy and free-energy calculations. Brackets indicate the location of the mouse IL-10 RNAi employed in these experiments. The sequence begins at nucleotide 317 and appears exposed in a hairpin. (B) Acrylamide gel of RNA stained with ethidium bromide. Lane 1 is dH2O as a negative control, lane 2 is dsRNAi, lane 3 is ssRNAi strand 1, and lane 4 is ssRNAi strand 2. The size of the ladder on the far left (y-axis) is given in nucleotides. The arrow indicates the band for dsRNAi.

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    RNAi inhibits cellular growth in a time-dependent manner. The graph shows the cell count over 72 hr of no treatment (dashed line), treatment with 2 µM scrambled IL-10 dsRNA (dsScr, dotted line), and treatment with 2 µM RNAi IL-10 (RNAi, solid line). The x-axis corresponds to the number of days of treatment and the y-axis to the cell number. The graph is representative of triplicate IL-10 RNAi treatments.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    RNAi effectively limits cellular proliferation in a dose-dependent manner. Columns corresponds to treatment groups, with the mean OD values for MTT analysis plotted on the y-axis and the bars corresponding to the standard error of the mean. (A) Cells treated for 16.5 hr with varying concentrations of IL-10 RNAi (RNAi) or scrambled IL-10 dsRNA (dsScr) (0.2-2.0 µM): Gray bar, 0.2 µM ; horizontal stripe, 0.5 µM; diamond bar, 1.0 µM; hatched bar, 2.0 µM. Error bars are the SEM of triplicate results. Asterisks indicate P < 0.05 for a Student's t-test comparing dsScr to RNAi. (B) Cells treated for 48 hr with 2 µM RNAi or dsScr. Error bars are the SEM of triplicate results. Asterisks indicate P < 0.05 for a Student's t-test comparing dsScr to RNAi.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    RNAi induces a G2/M block and apoptosis. Histograms showing PI staining of DNA content, with the x-axis reflecting DNA content and the y-axis the cell number. Arrows indicate sub-G1 cells (apoptotic). Flow cytometric determination of cell cycle distribution of LNC cells following 24 hr (A-C) or 42 hr (D-F) of treatment: Control (A) and (D), scrambled IL-10 dsScr (B) and (E), RNAi IL-10 (RNAi) (C) and (F). The distribution of cells in each phase of the cell cycle following treatment was summed to give the percentage of cycling cells. The percentage of apoptotic cells is expressed as a percentage of the whole gated population.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5

    IL-10 protein analysis by ELISA. The amount of IL-10 protein in LNC supernatants was measured by ELISA. Columns correspond to groups treated for 72 hr with either 2 µM IL-10 RNAi (hatched bar), 2 µM dsScr (black bar), or untreated control (gray bar). Error bars are the SEM of triplicate results. Asterisks indicate P < 0.05 for a Student's t-test comparing dsScr to RNAi.

  • Figure 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6

    IL-10 message analysis by real-time RT-PCR. Fluorescence of Taqman™ reporter dyes for IL-10 and ribosomal 18S are labeled. Black curves represent results from LNC cells treated for 72 hr with 2 µM IL-10 RNAi. Gray curves are untreated control. Ribosomal 18S was used to normalize samples. The graph is representative of three real-time PCR reactions.

  • Figure 7
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7

    Semiquantitative RT-PCR analysis of IL-10 and critical cell cycle components. (A) Graphic analysis of semiquantitative RT-PCR for IL-10, cdc25C, p27, IL-10 R1, IL-10 R2 and TNF-alpha RNA levels after 48 hours of treatment with either 2 µM IL-10 RNAi (hatched bars), 2 µM dsSCR (gray bars) as compared to an untreated control. Numbers correspond to the percentage of control values from triplicate gels and error bars to the SEM. Asterisks indicate P < 0.05 for a Student's t-test comparing dsScr to RNAi. (B) Representative PCR gels stained with ethidium bromide: Control (lane 1), 2 µM dsSCR (lane 2) and 2 µM IL-10 RNAi (lane 3).

  • Figure 8
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8

    Semiquantitative RT-PCR analysis of apoptosis regulators. (A) Graphic analysis of semiquantitative RT-PCR for Bcl2, Bcl7C, and Bax RNA levels after 48 hr of treatment with either 2 µM IL-10 RNAi (hatched bars) or 2 µM dsScr (gray bars) when compared to an untreated control. Numbers represent percent of control values from triplicate gels. Error bars are SEM. Asterisks indicate P < 0.05 for a Students t-test comparing dsScr to RNAi. (B) Representative PCR gels stained with ethidium bromide. Lane 1 is control, lane 2 is 2 µM dsScr and lane 3 is 2 µM IL-10 RNAi.

Tables

  • Figures
  • Table 1

    Genes, PCR primers and products.

    Gene PCR Primer Sequences PCR Product
    Name GI No. Size (bp) Nucleotides Spanned
    IL-10 6754317 5':  CGGGAAGACAATAACTG 186 148-333
    3':  CATTTCCGATAAGGCTTGG
    IFN-gamma 28501526 5':  AACGCTACACACTGCATCTTG 237 112-348
    3':  GACTTCAAAGAGTCTGAGG
    TNF-alpha 7305584 5':  AGTGGTGCCAGCCGATGGGTTGT 253 537-789
    3':  GCTGAGTTGGTCCCCCTTCTCCAG
    Bax 17390521 5':  CCAAGAAGCTGAGCGAGTGTCTC 146 235-381
    3': AGTTGCCATCAGCAAACATGTCA
    Bcl2 6753167 5': CAGCTGCACCTGACG 303 343-641
    3': AGAGACAGCCAGGAG
    Bcl7C 13542972 5': GGCGACCATCGAGAAGGTCCG 318 305-622
    3': GTTGGTGATCCAGGGCGGC
    cdc25C 13435584 5': CACCAGTTTAAAGGCATTGG 230 519-748
    3': GACTTAAGCCCTTGGCGTCC
    IL-10R1 6680388 5': CTGAGCCTAGAATTCATTGCATAC 388 122-509
    3': CATAGATGATGCCGTCCATTGCTT
    IL-10R2 17646387 5': CCACCCCCTGAGAAGGTC 599 80-678
    3': CAGGAAGGGGTTATTTCG
    p27 17939614 5': GGCTCTGCTCCATTTGACTG 393 342-734
    3': CCTGCCATTCGTATCTGCCC
    IL-19 28482156 5': CCGGATCCCTCAGTTCATATCTACAGTCTTAG 477 166-643
    3': TTGAATTCAGGCTGCAGGAGTTTCCAGATG
    IL-22 8393604 5': AAATGCGCTGCCCGTCAACAC 192 146-337
    3': ACCTGCTTCATCAGGTAGCAC
    IFN-lambda 27261790 5': GCGGTACCATGACTGGGGACTGCACGCCAGTG 595 9-603
    3': CGGAATTCAGGTGGACTCAGGGTGGGTTGA
    HPRT 13435620 5': GTTGGATACAGGCCAGACTTTGTTG 162 575-737
    3': GATTCAACTTGCGCTCATCTTAGGC
PreviousNext
Back to top
Cancer Immunity Archive: 4 (1)
January 2004
Volume 4, Issue 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
RNA interference of IL-10 in leukemic B-1 cells
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
RNA interference of IL-10 in leukemic B-1 cells
Brian A. McCarthy, Amal Mansour, Yi-Chu Lin, Sergei Kotenko and Elizabeth Raveche
Cancer Immun January 1 2004 (4) (1) 6;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
RNA interference of IL-10 in leukemic B-1 cells
Brian A. McCarthy, Amal Mansour, Yi-Chu Lin, Sergei Kotenko and Elizabeth Raveche
Cancer Immun January 1 2004 (4) (1) 6;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and methods
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Expression of CD1c enhances human invariant NKT cell activation by α-GalCer
  • Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma
  • Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement